To include your compound in the COVID-19 Resource Center, submit it here.

Extending Exonics

How TCG is helping gene editing play Exonics transition from virtual to physical

After courting investment offers from several undisclosed VCs and pharmas, gene editing company Exonics Therapeutics Inc. signed on to a $40 million series A from The Column Group because of the VC’s hands-on approach to helping newcos transition from virtual to

Read the full 411 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE